Company Profile

Macrocyclics Inc
Profile last edited on: 9/3/19      CAGE: 3CCR2      UEI: WMZUMZ73Z5M5

Business Identifier: Metal chelators
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

700 Klein Road
Plano, TX 75074
   (469) 786-6060
Location: Single
Congr. District: 03
County: Collin

Public Profile

In October 2011, Macrocyclics was acquired by Avera Med, a subsidiary of renewable energy company Avera that is devoted on developing cancer therapeutics. Macrocyclics is a research & development company actively engaged in developing novel ligands for biomedicine and it is a trusted name in metal-ligand chelating technologies. The firm's primary technology platforms are high performance bifunctional ligands for targeting radionuclides to cancer cells and novel magnetic resonance imaging (MRI) agents. Macrocyclics has been actively developing new synthetic methodologies and cutting edge applications which have relied upon customized chelating agents since its inception. Macrocyclics has created an extensive IP portfolio and possesses world-recognized expertise in high performance chelation chemistries relevant to a broad spectrum of medical applications including bifunctional chelating agents, contrast enhancement media and molecular imaging. The firm's most recent technologies include novel techniques for rapid labeling of biomolecules with chelating agents, paramagnetic magnetization transfer and pH responsive contrast agents.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2014 1 NIH $165,922
Project Title: A Single Injection Method of Determining in Vivo pH by MRI
2003 1 NIH $159,642
Project Title: Copper Complexes for Cancer Imaging and Therapy
2003 2 NIH $182,232
Project Title: MRI agents that report the extracellular pH of tumors

Key People / Management

  Julien Dodet -- President

  Garry Kiefer -- CEO and Director of Research

  A Dean Sherry -- Founder and Chief Scientific Advisor

  Dhurjati S Mudigonda

  Tom Pennington -- Secretary

  Julien Torgue -- Board of DIrectors

  Kuangcong Wu

Company News